Genelux Statistics
Total Valuation
Genelux has a market cap or net worth of $119.79 million. The enterprise value is $99.84 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genelux has 44.29 million shares outstanding. The number of shares has increased by 23.03% in one year.
| Current Share Class | 44.29M |
| Shares Outstanding | 44.29M |
| Shares Change (YoY) | +23.03% |
| Shares Change (QoQ) | -0.14% |
| Owned by Insiders (%) | 9.09% |
| Owned by Institutions (%) | 17.12% |
| Float | 36.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.58 |
| P/TBV Ratio | 6.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.20 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -123.35% and return on invested capital (ROIC) is -75.77%.
| Return on Equity (ROE) | -123.35% |
| Return on Assets (ROA) | -64.27% |
| Return on Invested Capital (ROIC) | -75.77% |
| Return on Capital Employed (ROCE) | -168.92% |
| Weighted Average Cost of Capital (WACC) | 5.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.59% in the last 52 weeks. The beta is 0.16, so Genelux's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -29.59% |
| 50-Day Moving Average | 4.05 |
| 200-Day Moving Average | 3.86 |
| Relative Strength Index (RSI) | 33.10 |
| Average Volume (20 Days) | 384,077 |
Short Selling Information
The latest short interest is 3.02 million, so 6.83% of the outstanding shares have been sold short.
| Short Interest | 3.02M |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 6.83% |
| Short % of Float | 8.39% |
| Short Ratio (days to cover) | 22.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.55M |
| Pretax Income | -31.87M |
| Net Income | -31.87M |
| EBITDA | -33.31M |
| EBIT | -33.55M |
| Earnings Per Share (EPS) | -$0.88 |
Full Income StatementBalance Sheet
The company has $20.92 million in cash and $1.62 million in debt, with a net cash position of $19.29 million or $0.44 per share.
| Cash & Cash Equivalents | 20.92M |
| Total Debt | 1.62M |
| Net Cash | 19.29M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 18.59M |
| Book Value Per Share | 0.49 |
| Working Capital | 16.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.37 million and capital expenditures -$758,000, giving a free cash flow of -$24.13 million.
| Operating Cash Flow | -23.37M |
| Capital Expenditures | -758,000 |
| Free Cash Flow | -24.13M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genelux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.03% |
| Shareholder Yield | -23.03% |
| Earnings Yield | -26.76% |
| FCF Yield | -20.25% |
Analyst Forecast
The average price target for Genelux is $19.75, which is 630.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.75 |
| Price Target Difference | 630.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 460.34% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genelux has an Altman Z-Score of -8.46 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.46 |
| Piotroski F-Score | 1 |
